- Atractylenolide II
-
- $80.00 / 1mL
-
2026-01-04
- CAS:73069-14-4
- Min. Order:
- Purity: 99.89%
- Supply Ability: 10g
- Atractylenolide II
-
- $0.00 / 25kg
-
2024-04-12
- CAS:73069-14-4
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 2000ton
- Atractylenolide II
-
- $0.00 / 20mg
-
2023-02-24
- CAS:73069-14-4
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
|
| | 2-ATRACTYLENOLIDE Basic information |
| Product Name: | 2-ATRACTYLENOLIDE | | Synonyms: | ASTEROLIDE;2-ATRACTYLENOLIDE;Atractylenolide II (Asterolide);(4aS,8aR,9aS)-4a,5,6,7,8,8a,9,9a-Octahydro-3,8a-dimethyl-5-methylenenaphtho[2,3-b]furan-2(4H)-one;Atractylenolide Ⅱ;Atractylenolide II, BR;Atracylenolide II;Naphtho[2,3-b]furan-2(4H)-one, 4a,5,6,7,8,8a,9,9a-octahydro-3,8a-dimethyl-5-methylene-, (4aS,8aR,9aS)- | | CAS: | 73069-14-4 | | MF: | C15H20O2 | | MW: | 232.32 | | EINECS: | | | Product Categories: | chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract | | Mol File: | 73069-14-4.mol |  |
| | 2-ATRACTYLENOLIDE Chemical Properties |
| Melting point | 150-152 °C(Solv: ethyl ether (60-29-7)) | | Boiling point | 378.0±41.0 °C(Predicted) | | density | 1.09±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | Soluble in chloroform | | form | powder | | color | White |
| | 2-ATRACTYLENOLIDE Usage And Synthesis |
| Chemical Properties | White crystalline powder, soluble in organic solvents such as methanol, ethanol, and DMSO. It is derived from Atractylodes macrocephala Koidz. | | Uses | food and beverages | | Definition | ChEBI: Atractylenolide II is a sesquiterpene lactone. | | in vivo | Atractylenolide II (12.5-25 mg/kg; Oral gavage; 14 days) has antitumor effect in a B16 xenograft mouse model[3].
Atractylenolide II (10-60 mg/kg/d; Intraperitoneal injection; 8 weeks) improves myocardial fibrosis and oxidative stress in spontaneously hypertensive rats[4]. | Animal Model: | C57/BL6 mice with a B16 xenograft model[3] | | Dosage: | 12.5 and 25 mg/kg | | Administration: | Oral gavage (i.g.); 14 days | | Result: | Significantly inhibited tumor growth.
Inhibited the activation/phosphorylation of STAT3 and Src.
|
| Animal Model: | Spontaneous hypertension rats[4] | | Dosage: | 10, 30 and 60 mg/kg/d | | Administration: | Intraperitoneal injection (i.p.); 8 weeks | | Result: | Improved the body weight of spontaneous hypertension rats and enhanced myocardial function in a dose-dependent manner.
Effectively reduced cardiomyocyte apoptosis.
Inhibited the Collagen I, α-SMA, Fibronectin and Vimentin mRNA and protein expression levels.
Ameliorated oxidative stress by improving the activities of SOD and GSH-PX and lowering the contents of H2O2 and MDA, which reached about 80%. |
| | IC 50 | p-STAT3 |
| | 2-ATRACTYLENOLIDE Preparation Products And Raw materials |
|